Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedPAC Urges Restraint In Granting Add-On Payments For New Technologies

This article was originally published in The Gray Sheet

Executive Summary

CMS should be selective in awarding new technology add-on payments to promote hospital efficiency, according to the Medicare Payment Advisory Commission

You may also be interested in...



Two More Devices Qualify For New Technology Add-On Payments – IPPS Rule

Medtronic remains the only device firm to qualify for CMS' elusive new technology add-on payments, with three out of its four applications accepted

Two More Devices Qualify For New Technology Add-On Payments – IPPS Rule

Medtronic remains the only device firm to qualify for CMS' elusive new technology add-on payments, with three out of its four applications accepted

AdvaMed, MDMA Take Issue With CMS’ New Tech Add-On Payment Policy

CMS' proposed redefinition of "new" technologies contradicts Medicare statute, according to AdvaMed

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel